Drug Search Results
More Filters [+]

GDC-695

Alternative Names: gdc-695, gdc 695, gdc695
Latest Update: 2021-12-13
Latest Update Note: News Article

Product Description

Gage Development Company is developing GDC-695 as a treatment for actinic keratosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02952898)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Balmoral Medical company
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GDC-695

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Keratosis, Actinic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GDC-695-001

P3

Completed

Keratosis, Actinic

2017-07-11

46%

Recent News Events